CytoMed Therapeutics Files 6-K for June 30, 2024 Period

Ticker: GDTC · Form: 6-K · Filed: Sep 30, 2024 · CIK: 1873093

Cytomed Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyCytomed Therapeutics LTD (GDTC)
Form Type6-K
Filed DateSep 30, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer

TL;DR

CytoMed Therapeutics filed a routine 6-K for its June 30, 2024 period. No major news.

AI Summary

CytoMed Therapeutics Limited filed a Form 6-K on September 30, 2024, reporting for the financial period ended June 30, 2024. The company, previously known as CytoMed Therapeutics Pte. Ltd. until July 16, 2021, is a foreign private issuer based in Singapore. This filing does not appear to contain specific financial figures or operational updates beyond its classification and reporting period.

Why It Matters

This filing indicates CytoMed Therapeutics is meeting its reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges.

Risk Assessment

Risk Level: low — This is a standard periodic filing by a foreign private issuer with no new material information disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the financial period ended June 30, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 1 Commonwealth Lane #08-22, Singapore 149544.

When did the company change its name?

The company's former name was CytoMed Therapeutics Pte. Ltd., and the date of the name change was July 16, 2021.

What is the company's SIC code?

The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Is CytoMed Therapeutics filing its annual report on Form 20-F?

The filing indicates 'Yes' for the check mark indicating whether the registrant files or will file annual reports under cover of Form 20-F.

Filing Stats: 339 words · 1 min read · ~1 pages · Grade level 15.3 · Accepted 2024-09-30 07:00:23

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CytoMed Therapeutics Limited By: /s/ CHOO Chee Kong Name: CHOO Chee Kong Date: September 30, 2024 Title: Director and Chairman

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing